Pfizer Inc. (PFE)
Pfizer Inc. (PFE) Full-Year 2025 Financial Guidance Conference Call (Transcript)
Pfizer Inc. (NYSE:PFE ) Full-Year 2025 Financial Guidance Conference Call December 17, 2024 8:30 AM ET Company Participants Francesca DeMartino - Chief IRO and SVP Albert Bourla - Chairman and CEO David Denton - CFO Conference Call Participants Chris Schott - JPMorgan Geoff Meacham - Citibank Steve Scala - TD Securities Tim Anderson - Bank of America Chris Shibutani - Goldman Sachs Trung Huynh - UBS Vamil Divan - Guggenheim Evan Seigerman - BMO Capital Markets Operator Good day, everyone, and welcome to Pfizer's Analyst and Investor Call to Review Full Year 2025 Financial Guidance. Today's call is being recorded.
Pfizer Stock Rises as 2025 Outlook in Line With Expectations
Pfizer (PFE) shares rose Tuesday morning after the pharmaceutical company affirmed its full-year 2024 projections and issued 2025 revenue and adjusted profit guidance in line with analysts' estimates.
Guggenheim: Can see Pfizer reaching $10 billion in sales by 2030
Vamil Divan, Guggenheim Securities analyst, joins 'Squawk on the Street' to discuss Pfizer's guidance, how optimistic Divan is on Pfizer's product pipeline, and some of the complaints Pfizer has heard from activist investor Starboard.
2 Pharma Stocks to Watch: Pfizer, Teva Pharmaceutical
Pharma stocks Pfizer Inc (NYSE:PFE) and Teva Pharmaceutical Industries Ltd (NYSE:TEVA) are in the spotlight today.
Pfizer ticks up as expectation-matching guidance relieves investors
Pfizer Inc (NYSE:PFE, ETR:PFE) shares ticked up on Tuesday after the pharmaceutical giant appeared to offer relief for investors with guidance for the coming year. Revenue should grow by up to 5% next year to between $61.0 billion and $64.0 million, Pfizer signalled in a statement on Tuesday.
Pfizer Does Not Anticipate Material Changes To US Vaccine Policy From The Incoming Administration In 2025
On Tuesday, Pfizer Inc. PFE released its full-year 2025 financial guidance, projecting revenues between $61.0 billion and $64.0 billion compared to a consensus of $63.28 billion.
Pfizer Stock Rises as Drug Giant Sees 2025 Revenue of $61 Billion to $64 Billion
The company anticipates adjusted earnings of between $2.80 and $3 a share in 2025. Analysts had been expecting adjusted earnings of $2.86.
Pfizer forecasts 2025 profit in line with expectations
Drugmaker Pfizer on Tuesday said it was expecting its 2025 profits to be nearly in line with Wall Street expectations as it seeks to fend off criticism over its turnaround strategy from activist hedge fund Starboard Value.
What To Expect When Pfizer Outlines Its 2025 Financial Outlook On Tuesday?
Pfizer Inc. PFE will conduct an investor call on Tuesday to provide full-year 2025 financial guidance.
Pfizer: Lowest Levels In A Decade Is An Opportunity With A Dividend Yield Exceeding 6.5%
Pfizer's shares have significantly underperformed, but the current valuation and high dividend yield present a compelling value play. Despite revenue declines and potential regulatory risks, Pfizer remains a cash-generating machine with strong liquidity and a robust drug pipeline. Pfizer's operational improvements, debt reduction, and consistent dividend growth signal a turnaround, making it an attractive investment at current depressed levels.
Prediction: These Could Be the Best-Performing Pharma and Biotech Stocks Through 2030
Pharmaceutical and biotech stocks often are seen as steady and safe options for investors for one particular reason. Patients need their medications, so regardless of the economic environment, these companies generally see at least stability in revenue.
Pfizer: Irrational Anti-Vaccine Fear
Pfizer's stock has become appealing due to irrational vaccine fears. Market fears about RFK Jr.'s potential anti-vaccine stance are likely overblown, as neither he nor Trump have indicated plans to block vaccines. Pfizer's strong growth in oncology and specialty care, along with cost-cutting measures, suggest the stock is undervalued at below 10x EPS guidance.
